Expertise in
12
conditions

Dr. Joseph Aisner

Oncology
Rutgers Cancer Institute Of New Jersey
195 Little Albany St, 
New Brunswick, NJ 
Expertise in
12
conditions
Rutgers Cancer Institute Of New Jersey
195 Little Albany St, 
New Brunswick, NJ 

Overview

Joseph Aisner is an Oncologist practicing medicine in New Brunswick, New Jersey.

Dr. Aisner is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Thyroid Cancer, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NJ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Rutgers Cancer Institute of New Jersey
195 Little Albany St, New Brunswick, NJ 08901
Other Locations
Office
66 W Gilbert St Fl 2, Tinton Falls, NJ 07701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
Enrollment Status: Completed
Publish Date: November 21, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: February 09, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

45 Total Publications

A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Journal: Oncotarget
Published: April 10, 2023
Similar Doctors
Expertise in
26
conditions
Dr. Matthew Matasar
Hematology | Oncology
Expertise in
26
conditions
Dr. Matthew Matasar
Hematology | Oncology

Rutgers Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (0.1 miles away)
732-475-0824
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is a Hematologist and an Oncologist practicing medicine in New Brunswick, New Jersey. Dr. Matasar is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Expertise in
13
conditions
Dr. Andrew Evens
Hematology | Oncology
Expertise in
13
conditions
Dr. Andrew Evens
Hematology | Oncology

The Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (0.1 miles away)
862-445-1542
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Evens is a Hematologist and an Oncologist practicing medicine in New Brunswick, New Jersey. Dr. Evens is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Evens is currently accepting new patients.

Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology
Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (32.1 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Moskowitz is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses T-Cell Lymphoma, Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Frequently Asked Questions about Dr. Joseph Aisner

How do I make an appointment with Dr. Joseph Aisner?

You can book an appointment with Dr. Joseph Aisner by calling their office at 732-235-2465. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph Aisner a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph Aisner is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph Aisner specialize in?

While Dr. Joseph Aisner is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Thyroid Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Joseph Aisner participate in research or clinical trials?

Yes. Dr. Joseph Aisner has published 45 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Joseph Aisner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aisner's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile